arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

GeneDx Holdings Corp.

WGS
$64.36 ▼ -5.08 (-7.32%) at close
Healthcare ·Services-Health Services ·USServices-Health Services
27 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
36
Health
Weak
Bearish
auto_awesome

Analytical Summary

GeneDx Holdings Corp. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.9B
Dividend Yield —
Revenue Growth 11.4% ↘
Op. Margin -15.3% ↗
ROIC -4.9% ↗
FCF / Share $-1.32 →
Trailing P/E —
Price / Book 7.9x
FCF Yield —
Debt / Equity 0.41
info Valuation on last close. End-of-day price, Nov 5, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$114.44M
↑ +11.4% —
Net Income Profit after all expenses
$-17.74M
↑ +72.0% —
Operating Margin Operating profit as % of sales
-15.3%
↑ +72.9% 23th
FCF / Share Free cash flow per share
$-1.32
↑ +0.7% —
Long-Term Debt Long-term obligations
$100.00M
— 0.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
27
Returns ↑
37
Financial Health ↑
58
Cash Quality
12

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 8 years · 27 quarters